Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report) shares gapped down before the market opened on Monday . The stock had previously closed at $16.38, but opened at $16.02. Sionna Therapeutics shares last traded at $15.00, with a volume of 5,755 shares changing hands.
Wall Street Analyst Weigh In
SION has been the topic of a number of recent analyst reports. Guggenheim assumed coverage on Sionna Therapeutics in a research report on Tuesday, March 4th. They issued a "buy" rating and a $45.00 price objective on the stock. Stifel Nicolaus started coverage on Sionna Therapeutics in a research note on Tuesday, March 4th. They issued a "buy" rating and a $32.00 target price on the stock. TD Cowen assumed coverage on Sionna Therapeutics in a research report on Tuesday, March 4th. They set a "buy" rating for the company. Finally, Wall Street Zen lowered Sionna Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd.
Read Our Latest Report on SION
Sionna Therapeutics Stock Performance
The company's 50-day simple moving average is $13.16.
Sionna Therapeutics (NASDAQ:SION - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.62) EPS for the quarter, missing analysts' consensus estimates of ($0.45) by ($0.17).
Hedge Funds Weigh In On Sionna Therapeutics
Several institutional investors have recently modified their holdings of the company. Zimmer Partners LP bought a new stake in Sionna Therapeutics in the 1st quarter worth approximately $2,484,000. Alyeska Investment Group L.P. purchased a new position in shares of Sionna Therapeutics during the first quarter worth approximately $1,948,000. Charles Schwab Investment Management Inc. purchased a new position in shares of Sionna Therapeutics during the first quarter worth approximately $676,000. RA Capital Management L.P. bought a new stake in shares of Sionna Therapeutics in the 1st quarter worth approximately $109,258,000. Finally, Baker BROS. Advisors LP purchased a new stake in shares of Sionna Therapeutics in the 1st quarter valued at $4,184,000.
Sionna Therapeutics Company Profile
(
Get Free Report)
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.
Recommended Stories
Before you consider Sionna Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sionna Therapeutics wasn't on the list.
While Sionna Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
